液體栓塞市場規模、佔有率和趨勢分析 |全球| 2026–2032年

2025年全球液體栓塞市場規模約1.55億美元。預計該市場將以1.4%的複合年成長率成長，到2032年達到1.71億美元。

本報告重點關注全球液體栓塞市場，該技術主要用於動靜脈畸形（AVM）和其他需要閉塞標靶血管的血管疾病的血管內治療。該報告對銷售量、手術量、平均售價（ASP）、市場規模、成長率和企業市場占有率進行了定量分析，並包含截至2022年的歷史數據和截至2032年的預測數據。

受人口結構變化和微創神經血管手術日益普及的推動，預計需求將逐步成長。新興地區由於介入治療的可近性不斷提高，成長將更為顯著；而成熟市場由於市場飽和以及替代治療技術的出現，預計將保持相對穩定。

持續的價格壓力、激烈的競標以及日益加劇的市場競爭預計將在預測期內拉低平均售價（ASP），即使銷量成長，也會限制整體市場價值的擴張。這一趨勢反映了市場的一個特點，即細分市場的價格下降部分抵消了銷售的適度成長。

市場概覽

全球液體栓塞市場是神經血管介入領域的細分市場。液體栓塞劑被注入異常血管網路以阻斷血流，從而降低出血風險，並使後續的手術或放射外科治療更加完善。該市場呈現溫和穩定的成長態勢，主要得益於微創神經血管技術的逐步普及以及新興市場醫療服務可近性的提升。然而，平均售價（ASP）的下降以及其他血管治療平台的競爭壓力在一定程度上抵消了這一成長。

新興市場是該領域最重要的成長機會。隨著亞太、拉丁美洲和中東地區神經血管介入治療的普及，這些地區的介入手術數量預計將以高於北美和西歐的速度成長。北美和西歐的介入性手術應用較為成熟，市場滲透率也相對穩定。這種成長貢獻的地域性轉變預計將在整個預測期內影響市場參與企業的業務重點。

由於其良好的滲透性，非黏性液體栓塞術已成為某些類型動靜脈畸形（AVM）的首選治療方法。非黏性配方可實現精準控釋，透過反覆、分步的小劑量輸注、暫停和恢復，即可栓塞較大的病灶，且不會出現材料過早硬化的情況。這些臨床優勢使得非黏性產品即使在競爭日益激烈和替代栓塞方法不斷湧現的情況下，仍能維持市場主導地位。

• 可脫卸式微導管的引入解決了以往使用液體栓塞劑時最嚴重的併發症之一：導管沾黏。這些裝置能夠實現可控的、長時間的輸注，避免導管永久嵌入栓塞劑中，從而提高了液體栓塞術的實際安全性，並減少了以往限制其在特定患者群體和臨床環境中應用的障礙。

市場促進因素

減少導管黏附

導管沾黏一直是液體栓塞術中重要的併發症，限制了其應用並增加了手術風險。可拆卸尖端微導管透過緩慢、可控且持續的輸註解決了這個問題，確保栓塞完全，同時避免導管嵌入組織。可拆卸尖端設計使得輸注後導管遠端能夠輕鬆分離，無需強行拔出粘連的導管，從而降低了出血和導管碎片脫落的風險。其他液體栓塞製劑的研發，例如正丁基氰基丙烯酸酯與碘油和碘帕醇的組合，可望進一步降低導管粘連率，提高手術安全性，並拓展液體栓塞術的選擇範圍。

穿透能力

液體栓塞，尤其是非黏性配方，其滲透能力使其在臨床上優於其他栓塞方法。非黏性化合物可透過重複、遞增注射少量藥物，使更大比例的病灶得以栓塞，並在凝固前完全滲透至異常血管網路深處。這種方法可在單次治療中更徹底地栓塞動靜脈畸形（AVM），減少逐步治療的需要。因此，在以完全閉塞病灶為臨床目標的複雜病例中，液體栓塞是首選方法。可暫停和恢復注射而不會過早凝固的特性，使醫生在手術過程中擁有更大的控制力，因此更適用於需要精準注射的複雜病例。

市場限制

安全隱患

• 使用液態栓塞劑進行動靜脈畸形（AVM）栓塞術有導管意外滯留的風險，這可能導致出血、死亡或導管碎片移位至身體其他部位等嚴重併發症。一項研究表明，使用Onyx栓塞劑進行栓塞術後導管滯留的發生率約為3%。監管和合規性問題也影響著該領域的商業性趨勢。Medtronic力子公司ev3承認，其銷售的Onyx劑量超過了核准用於非適應症神經血管外和顱內治療的劑量。調查發現，銷售負責人曾提供針對仿單標示外使用的具體操作指引。這些安全和合規性案例促使人們對液體栓塞劑的使用進行更嚴格的審查，並提高了相關市場對醫生培訓、操作規程和監管的要求。

新技術的引入

多種新型栓塞和神經血管器械正陸續進入市場，加劇了液體栓塞術的競爭壓力。儘管液體栓塞術仍然是動靜脈畸形（AVM）最常用的治療方法，但其與動脈瘤專用器械在手術操作上存在一些重疊，並且在適應症重疊的領域，其他替代技術正逐漸獲得認可。例如，「Pipeline」栓塞裝置等血流導向裝置主要用於治療頸部較寬的大型或巨大型腦動脈瘤，其日益普及反映了針對特定神經血管疾病的專用器械解決方案的更廣泛趨勢。Medtronic）和Microvention都在尋求收購開發動脈瘤栓塞器械的公司，這表明業界將繼續投資於能夠在特定手術場景中與液體栓塞術競爭或取代液體栓塞術的平台。

目錄

調查方法

• 第一步：專案推出與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查分析：基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場發布
• 步驟九：客戶回饋與市場監測

全球關稅的影響

液態栓塞市場

• 執行摘要
  • 全球液體栓塞市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
• 調查方法的數量
• 市場分析與預測
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭對手市佔率分析

附錄

The global liquid embolic market was valued at approximately $155 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 1.4%, reaching $171 million by 2032.

This report covers the global market for liquid embolics used primarily in the endovascular treatment of arteriovenous malformations (AVMs) and other vascular conditions requiring targeted vessel occlusion. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

Unit demand is expected to rise gradually, supported by demographic trends and the broader adoption of minimally invasive neurovascular procedures. Growth will be more pronounced in emerging regions where access to interventional care is improving, while mature markets remain relatively stable due to saturation and the availability of alternative treatment technologies.

Ongoing pricing pressure, competitive bidding, and increasing market competition are expected to push ASPs downward over the forecast period, constraining overall market value expansion even as unit volumes grow. This dynamic characterizes a market where modest volume gains are partially offset by price erosion at the segment level.

Market Overview

The global liquid embolic market is a specialized segment within the neurovascular intervention space. Liquid embolics are injected into abnormal vessel networks to block blood flow, reducing the risk of hemorrhage and enabling more complete surgical or radiosurgical follow-up treatment. The market is characterized by slow, steady growth driven by gradual adoption of minimally invasive neurovascular techniques and improving access to care in emerging markets, partially offset by ASP erosion and competitive pressure from alternative vascular treatment platforms.

Emerging markets represent the most meaningful growth opportunity in this segment. As access to interventional neurovascular care expands across Asia-Pacific, Latin America, and the Middle East, procedural volumes in these regions are expected to grow faster than in North America or Western Europe, where procedure adoption is more mature and market penetration is relatively stable. This geographic shift in growth contribution is expected to shape commercial priorities for market participants over the forecast period.

The penetration capabilities of non-adhesive liquid embolics have established them as the preferred treatment approach for certain AVM types. Non-adhesive formulations allow for controlled delivery and the ability to achieve greater nidus embolization through progressive small injections, pausing and resuming without the material hardening prematurely. These clinical advantages have supported market leadership for products with non-adhesive properties despite increased competitive pressure and the availability of alternative embolization approaches.

• The introduction of detachable tip microcatheters has addressed one of the most significant procedural complications historically associated with liquid embolic use: catheter adherence. By allowing controlled, prolonged injection times without the risk of the catheter becoming permanently embedded in the embolic material, these devices have improved the practical safety profile of liquid embolic procedures and reduced a barrier to adoption that had limited use in some patient populations and care settings.

Market Drivers

Reduction in Catheter Adherence

Catheter adherence has historically been a significant procedural complication associated with liquid embolic use, limiting adoption and increasing procedural risk. Detachable tip microcatheters have addressed this problem by allowing slow, controlled, and prolonged injection times that ensure complete embolization while avoiding catheter entrapment. The detachable tip design allows the distal portion of the catheter to separate cleanly after injection, eliminating the need to forcefully retract an adherent catheter and reducing the risk of hemorrhage or catheter fragment migration. The development of alternative embolic liquid formulations, including combinations of n-Butyl Cyanoacrylate with Lipiodol and Iopamidol, is also expected to further reduce catheter adherence rates and widen the range of liquid embolic options available with improved procedural safety profiles.

Penetration Capabilities

The penetration capability of liquid embolics, particularly non-adhesive formulations, represents a key clinical advantage over competing embolization approaches. Non-adhesive compounds can embolize a greater percentage of the nidus using progressive small injections, allowing the material to penetrate deeply and completely into the abnormal vessel network before solidifying. This approach supports more thorough AVM embolization in a single session, reducing the need for staged procedures and making liquid embolics the preferred treatment for complex cases where complete nidus occlusion is the clinical goal. The ability to pause and resume injection without premature hardening gives physicians greater control during the procedure, supporting adoption in demanding cases where precise delivery is required.

Market Limiters

Safety Concerns

• AVM embolization using liquid embolics carries the risk of unintentional catheter retention, which can lead to serious complications including hemorrhage, death, or migration of catheter fragments to other regions of the body. A study found the incidence of catheter retention following Onyx embolization to be approximately 3%. Regulatory and compliance concerns have also affected commercial dynamics in this segment: Medtronic's subsidiary ev3 pleaded guilty to charges related to the distribution of Onyx for unapproved indications outside the brain and in quantities exceeding those approved for intracranial use, with sales representatives having provided explicit procedural instructions for off-label applications. These safety and compliance events have contributed to heightened scrutiny around liquid embolic use, raising the requirements for physician training, procedural protocols, and regulatory oversight in affected markets.

Introduction of New Technology

A range of newer embolization and neurovascular devices are entering the market and presenting growing competitive pressure for liquid embolics. While liquid embolics remain most commonly used for AVM treatment, some procedural crossover with aneurysm-focused devices exists, and alternative technologies are capturing cases at the margin of overlapping indications. Flow diverter devices such as the Pipeline embolization device are used primarily for large or giant wide-necked brain aneurysms, and their growing adoption reflects a broader trend toward dedicated device-based solutions for specific neurovascular conditions. Both Medtronic and MicroVention have pursued acquisitions of companies developing aneurysm embolization devices, signaling ongoing industry investment in platforms that may compete with or displace liquid embolics in select procedural settings.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neurovascular device industry leaders and interventional physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals and neurovascular intervention centers.

Markets Covered and Segmentation

• The liquid embolic market is analyzed as a unified segment, assessed by unit volume, ASP, and market value with historical and forecast data provided:
• Liquid Embolics

Competitive Analysis

Medtronic was the leader in the global liquid embolic market in 2025. The company's Onyx Liquid Embolic System (LES) is the dominant product in this segment, composed of a non-adhesive compound that forms a soft and malleable polymer within the target vessel following injection. Onyx's non-adhesive properties enable more controlled delivery, allow surgeons to achieve deeper nidus penetration through progressive small injections, and provide a longer working window compared to adhesive alternatives. Medtronic's market leadership in liquid embolics is supported by the extensive clinical evidence base built around Onyx and by the company's broader neurovascular portfolio, which spans flow diverter and aneurysm embolization platforms alongside liquid embolic products.

Johnson and Johnson held the second-leading position in the liquid embolic market in 2025 through its TruFill system. TruFill offers a cyanoacrylate-based liquid embolic for the endovascular treatment of cerebral AVMs, providing an adhesive formulation alternative for physicians who prefer this approach. The product maintains Johnson and Johnson's participation in the neurovascular embolization segment and offers a distinct clinical profile from non-adhesive systems for specific procedural scenarios.

Terumo was the third-leading competitor in the liquid embolic market in 2025. The company competes through its Precipitating Hydrophobic Injectable Liquid (PHIL) system, a non-adhesive liquid embolic that provides an alternative to Onyx for AVM embolization. PHIL's formulation delivers controlled, non-adhesive injection characteristics comparable to Onyx, giving physicians an alternative non-adhesive platform and introducing competitive pricing pressure within the non-adhesive liquid embolic category.

Technology and Practice Trends

• Detachable tip microcatheters: These devices have meaningfully reduced catheter adherence complications, enabling controlled prolonged injection times and improving the practical safety profile of liquid embolic procedures in AVM treatment.
• Non-adhesive liquid formulations: Non-adhesive compounds such as Onyx and PHIL provide more controlled delivery than adhesive cyanoacrylate alternatives, supporting deeper nidus penetration and reducing the risk of premature occlusion during injection.
• Alternative embolic liquid development: New formulations such as n-Butyl Cyanoacrylate combined with Lipiodol and Iopamidol are being developed to further reduce catheter adherence rates and expand the range of available liquid embolic options.
• AVM embolization as primary indication: Liquid embolics remain the standard approach for AVM treatment, with clinical preference maintained by their penetration depth, controlled delivery characteristics, and established long-term outcomes.
• Aneurysm device competition: Flow diverters and intrasaccular devices are growing in adoption for aneurysm treatment and present competitive alternatives at the margin of indications where liquid embolics have historically played a role.
• Emerging market volume growth: Improving access to interventional neurovascular care across Asia-Pacific, Latin America, and the Middle East is expected to drive the most significant unit volume growth over the forecast period, with mature markets remaining comparatively stable.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities within the global liquid embolic market, and which regions are expected to contribute the most meaningful unit volume growth through 2032?
• How are detachable tip microcatheters and next-generation embolic liquid formulations improving the safety and adoption profile of liquid embolic procedures globally?
• What impact are flow diverters, intrasaccular devices, and other alternative neurovascular platforms having on liquid embolic procedure volumes and market share?
• How is pricing pressure and competitive bidding constraining market value growth even as unit volumes rise, and what are the implications for commercial planning?
• Which companies lead the market and how are their non-adhesive and adhesive product platforms differentiated for AVM and other vascular indications?
• What are the safety and regulatory dynamics shaping physician adoption, training requirements, and commercial strategy for liquid embolic products?
• What is the long-term outlook for AVM embolization as the primary indication, and how might procedural crossover with aneurysm treatment evolve over the forecast period?
• What are the key risks to growth, including ASP erosion, safety-related market headwinds, and competition from dedicated aneurysm embolization platforms?

The Global Liquid Embolic Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, and plan commercial strategy across a slow-growth market shaped by technology competition and regional access dynamics.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Liquid Embolic Market

• 6.1 Executive Summary
  • 6.1.1 Global Liquid Embolic Market Overview
  • 6.1.2 Competitive Analysis
  • 6.1.3 Procedures Included
  • 6.1.4 Markets Included
  • 6.1.5 Regions Included
• 6.2 Introduction
• 6.3 Procedure Numbers
• 6.4 Market Analysis And Forecast
• 6.5 Drivers And Limiters
  • 6.5.1 Market Drivers
  • 6.5.2 Market Limiters
• 6.6 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 6-1: Liquid Embolic Market, Global, 2025 & 2032
• Chart 6-2: Liquid Embolic Procedures, Global, 2025
• Chart 6-3: Liquid Embolic Procedures by Region, Global, 2022 - 2032
• Chart 6-4: Liquid Embolic Market, Global, 2022 - 2032
• Chart 6-5: Leading Competitors, Liquid Embolic Market, Global, 2025

LIST OF FIGURES

• Figure 6-1: Liquid Embolic Procedures Covered
• Figure 6-2: Liquid Embolic Markets Covered
• Figure 6-3: Liquid Embolic Regions Covered, Global (1 of 2)
• Figure 6-4: Liquid Embolic Regions Covered, Global (2 of 2)
• Figure 6-5: Total Liquid Embolic Procedures, Global, 2022 - 2032
• Figure 6-6: Liquid Embolic Procedures by Region, Global, 2022 - 2032
• Figure 6-7: Liquid Embolic Procedures by Country, North America, 2022 - 2032
• Figure 6-8: Liquid Embolic Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-9: Liquid Embolic Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-10: Liquid Embolic Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-11: Liquid Embolic Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-12: Liquid Embolic Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-13: Liquid Embolic Procedures by Country, Middle East, 2022 - 2032
• Figure 6-14: Liquid Embolic Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-15: Liquid Embolic Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-16: Liquid Embolic Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-17: Liquid Embolic Procedures by Country, Africa, 2022 - 2032
• Figure 6-18: Liquid Embolic Market, Global, 2022 - 2032
• Figure 6-19: Units Sold by Region, Liquid Embolic Market, Global, 2022 - 2032
• Figure 6-20: Average Selling Price by Region, Liquid Embolic Market, Global, 2022 - 2032 (US$)
• Figure 6-21: Market Value by Region, Liquid Embolic Market, Global, 2022 - 2032 (US$M)
• Figure 6-22: Leading Competitors, Liquid Embolic Market, Global, 2025